Biomerica Inc (BMRA) 0.8200 $BMRA
Biomerica reports net income of USD26,544 for Q3
M2 - Wed Apr 16, 3:01AM CDT
Biomedical company Biomerica (OTCBB:BMRA) stated on Tuesday its net income of USD26,544 for the three months ended 28 February 2014.
Biomerica Announces Third Quarter Financial Results
Marketwire - Tue Apr 15, 7:19AM CDT
Biomerica, Inc. (OTCBB: BMRA) today reported net sales of $1,492,719 for the three months ending February 28, 2014, compared to $1,416,698 for the same period in the previous year. Sales for the nine months ending February 28, 2014 were $3,441,299, compared to $5,002,418.
Global Enteric Disease Testing Market 2014-2018: New Emerging Viruses and Bacteria Playing an Important Role in Diagnostics Industry
M2 - Wed Feb 26, 6:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/lrghlr/global_enteric) has announced the addition of the "Global Enteric Disease Testing Market 2014-2018" report to their offering. The analysts forecast the Global Enteric Disease Testing market to grow at a CAGR of 2.83 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing incidence of enteric diseases. The Global Enteric Disease Testing market has also been witnessing the emergence of new pathogens causing infections. However, the stringent regulatory approval could pose a challenge to the growth of this market. Key vendors dominating this space are Alere Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Cepheid Inc. and DiaSorin S.p.A. Other vendors mentioned in the report are Affymetrix Inc., Beckton, Dickenson and Co., Biomerica Inc., Coris BioConcept, Danaher Corp., Meridian Bioscience Inc., Quest Diagnostics Inc., R-Biopharm AG, and Trinity Biotech PLC. Commenting on the report, an analyst from the team said: Vendors are introducing new diagnostic tests for new found pathogens that are responsible for some other types of infectious diseases. These new pathogens include West Nile virus, respiratory syncytial virus, genital mycoplasma, C. difficile, norovirus, and rotavirus. C. difficile and rotavirus tests have seen the maximum level of acceptance in the market. Thus, the improvement in detection technology aiding in the identification of new pathogens is driving the need for enteric disease testing products. According to the report, one of the major drivers in the market is the increasing incidence of enteric diseases among the population, creating a need for testing methods that effectively diagnose diseases. For more information visit http://www.researchandmarkets.com/research/lr...al_enteric About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Concise Analysis on the International Enteric Disease Testing Market - Forecasts to 2019
M2 - Wed Feb 05, 5:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/v3x48h/enteric_disease) has announced the addition of the "Concise Analysis on the International Enteric Disease Testing Market - Forecasts to 2019" report to their offering. Various microbes responsible for enteric infections include salmonella, shigella, rotavirus, norovirus, c. difficile, cryptosporidium, vibrio and campylobacter. These diseases may range from asymptomatic to having mild to severe symptoms such as bloody diarrhea, abdominal cramps, stool containing blood or pus, fever and weight loss. Incubation period varies from few days to few weeks depending on the disease and severity. In order to reduce the chance of developing complications, these diseases needed to be diagnosed early. Earlier, diagnosis of enteric diseases relied on culture results of stool specimen that involved identification of causative pathogens in a culture medium. However, the trend is now shifting from culture methods to other diagnostic methods owing to limitations associated with culture tests. Major drawbacks associated with culture tests include high cost, labor intensive, requires sophisticated laboratory and a skilled person to perform the diagnosis. On the other hand, enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR) has made enteric infection diagnosis easy and fast. In developed regions such as North America and Europe, PCR based diagnosis is most recommended testing method for enteric diseases as it offers high sensitivity and specificity and is considered as easy, accurate, rapid and reliable method of diagnosis. Latest introductions in MALDI-TOF have also been developed for rapid diagnosis of whole organisms without destruction of infection sample. Asia-Pacific accounting for more than 50% of the total global population represents the most profitable market for enteric disease testing in terms of growth and potential. Key Topics Covered: 1 Preface 2 Executive Summary 3 Enteric Disease Testing Market Overview 4 Global Enteric Disease Testing Market 5 Global Enteric Disease Testing Market, By Geography, 2011 - 2019 6 Key Player Analysis for Enteric Disease Testing Market, 2012 7 Company Profiles Companies Mentioned: - Alere - Becton Dickinson & Company - Biomerica - Biomerieux - Bio-Rad - Cepheid - Coris Bioconcept - Diasorin - Meridian Bioscience - Quest Diagnostics - Trinity Biotech For more information visit http://www.researchandmarkets.com/research/v3...ic_disease
Merriman Capital Initiates on Biomerica, Inc. with a Buy Rating
Thomson Reuters ONE - Fri Jan 24, 9:29AM CST
SAN FRANCISCO - January 24, 2014 - Merriman Capital, Inc. ("Merriman"
, a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced that it has initiated equity research coverage of Biomerica, Inc. (OTCQB: BMRA) with a Buy rating and a $2.85 price target.
Biomerica Announces Completion of Strategic Investment
Marketwire - Wed Jan 22, 7:19AM CST
Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, today reported it has closed a strategic investment from its new China distribution partner. In total the new China partner has now invested $500,000 at $1.25 per share for 400,000 shares of Biomerica restricted common stock.
Prefeasibility Report on a Peanut Butter Manufacturing Plant
M2 - Fri Jan 17, 4:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/5kjt3t/prefeasibility) has announced the addition of the "Prefeasibility Report on a Peanut Butter Manufacturing Plant" report to their offering. Prefeasibility Report on a Peanut Butter Manufacturing Plant provides a techno-commercial roadmap for setting up a peanut butter manufacturing plant. The study, which has been done by one of the world's leading research and advisory firms, covers all the requisite aspects of the peanut butter industry. This ranges from macro overview of the market to micro details of the industry performance, processing & manufacturing requirements, project cost, project funding, project economics, expected returns on investment, profit margins, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who are planning to foray into the peanut butter industry in any manner. Key Questions Answered in This Report? - What are the key success and risk factors in the peanut butter industry? - How has the peanut butter market performed so far and how will it perform in the coming years? - What is the structure of the peanut butter industry and who are the key players? - What are the various unit operations involved in a peanut butter plant? - What is the total size of land required for setting up a peanut butter plant? - What are the machinery requirements for setting up a peanut butter plant? - What are the raw material requirements for setting up a peanut butter plant? - What are the utility requirements for setting up a peanut butter plant? - What are the manpower requirements for setting up a peanut butter plant? - What are the infrastructure costs for setting up a peanut butter plant? - What are the capital costs for setting up a peanut butter plant? - What are the operating costs for setting up a peanut butter plant? - What should be the pricing mechanism of various peanut butter products? - What will be the income and expenditures for a peanut butter plant? - What is the time required to break-even? *Please note that this is a prefeasibility report. It will be delivered to you within 10-12 days after the confirmation of payment Key Topics Covered: 1. Executive Summary 2. Introduction to the Peanut Butter Industry 3. Peanut Butter Industry Analysis 4. Processing & Manufacturing of Peanut Butter Products 5. Project Details, Requirements and Costs Involved 6. Peanut Butter Manufacturing Plant: Loans & Financial Assistance 7. Peanut Butter Manufacturing Plant: Project Economics 8. Appendix For more information visit http://www.researchandmarkets.com/research/5k...easibility About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Biomerica Inc falls to net loss of USD243,357 in Q2
M2 - Thu Jan 16, 9:46AM CST
Biomedical company Biomerica Inc (OTCBB:BMRA) on Wednesday reported a net loss of USD243,357, or USD0.03 per share, for the three months ended 30 November 2013.
GKN's Marcus Bryson to become President of UK trade organisation ADS Group
M2 - Wed Jan 15, 9:49AM CST
Aerospace
Biomerica Announces Second Quarter Financial Results
Marketwire - Wed Jan 15, 7:28AM CST
Biomerica, Inc. (OTCBB: BMRA) today reported net sales of $934,841 for the three months ended November 30, 2013, compared to $1,883,771 for the same period in the previous year. Net sales were $1,948,580 for the first six months of fiscal 2014 compared to $3,585,719 for the first six months in fiscal 2013.
10-Q: BIOMERICA INC
Edgar Online - Tue Jan 14, 3:25PM CST
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Biomerica to Supply Two of Its Point of Care Products to Multinational Pharmaceutical Company With Over $40 Billion in Sales
Marketwire - Tue Jan 14, 7:19AM CST
Biomerica, Inc. (OTCBB: BMRA) announced today it will supply two of its point of care products to a multinational pharmaceutical company for distribution in one European country with the possibility of expanding into multiple other countries throughout Europe. In addition, the multinational company is considering distribution of other Biomerica point of care products. The multinational pharmaceutical company that will be distributing Biomerica's products has over $40 billion in revenues and over 70,000 employees worldwide. The terms of the agreement were not disclosed and will remain confidential.
Global Enteric Disease Testing Market Forecasts & Opportunities Report, 2019
M2 - Fri Dec 06, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/n6mlmk/enteric_disease) has announced the addition of the "Global Enteric Disease Testing Market Forecasts & Opportunities Report, 2019" report to their offering. The global marketis expected to reach USD 3,643.4 million by 2019, up from USD 3,082.6 million in 2012, growing at a CAGR of 2.4% throughout the forecast period. Enteric diseases are gastrointestinal infections caused by a variety of microbes such as bacteria, viruses and parasites when they enter the body through the mouth or intestinal systems. Various microbes responsible for enteric infections include salmonella, shigella, rotavirus, norovirus, c. difficile, cryptosporidium, vibrio and campylobacter. These diseases may range from asymptomatic to having mild to severe symptoms such as bloody diarrhea, abdominal cramps, stool containing blood or pus, fever and weight loss. Incubation period varies from few days to few weeks depending on the disease and severity. In order to reduce the chance of developing complications, these diseases needed to be diagnosed early. The market for the enteric disease testing market has been segmented on the basis of different types of enteric diseases and their testing. Earlier, diagnosis of enteric diseases relied on culture results of stool specimen that involved identification of causative pathogens in a culture medium. However, the trend is now shifting from culture methods to other diagnostic methods owing to limitations associated with culture tests. Major drawbacks associated with culture tests include high cost, labor intensive, requires sophisticated laboratory and a skilled person to perform the diagnosis. On the other hand, enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR) has made enteric infection diagnosis easy and fast. In developed regions such as North America and Europe, PCR based diagnosis is most recommended testing method for enteric diseases as it offers high sensitivity and specificity and is considered as easy, accurate, rapid and reliable method of diagnosis. Latest introductions in MALDI-TOF have also been developed for rapid diagnosis of whole organisms without destruction of infection sample. Scope of the Report Diseases Bacterial Enteric Disease Testing Market - C.difficile Infection - Campylobacteriosis - Cholera - E.coli Infection - H.pylori Infection - Salmonellosis - Shigellosis Viral Enteric Disease Testing Market - Rotavirus Infection - Norovirus Infection Parasitic Enteric Disease Testing Market - Amebiasis - Cryptosporidiosis - Giardiasis Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Enteric Disease Testing Market Overview Chapter 4 Global Enteric Disease Testing Market Chapter 5 Global Enteric Disease Testing Market, By Geography, 2011 - 2019 (USD Million) Chapter 6 Key Player Analysis for Enteric Disease Testing Market, 2012 Chapter 7 Company Profiles - Alere, Inc - Becton Dickinson & Company - Biomerica, Inc - Biomerieux - Bio-Rad - Cepheid - Coris Bioconcept - Diasorin - Meridian Bioscience, Inc - Quest Diagnostics - Trinity Biotech For more information visit http://www.researchandmarkets.com/research/n6...ic_disease
Global Women's Health Diagnostic Testing Market Report 2013
M2 - Fri Nov 15, 5:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/nmsm9b/womens_health) has announced the addition of the "Global Women's Health Diagnostic Testing Market Report 2013" report to their offering. The purpose of this report is to describe the specific segment of the in vitro diagnostics (IVDs) market called women's health testing. This study includes contemporary and generally accepted clinical and analytical activities. This analysis examines clinical measurement devices, as well as their reagents and supplies, as utilized in hospitals, clinics and doctor's offices. Some diagnostic tests, which are marketed primarily as over-the-counter products, are included in this report. This report also includes other important tests like mammography, (i.e., tests which are not generally associated with IVD tests, but which are an important component of the overall women's health market). Key Topics Covered: 1. Overview 2. Introduction - Sector Overview 3. Women's Health Testing Market Analysis in Size, Growth and Share 4. Women's Health Testing Individual Markets 5. World Mammography Market 6. Women's Health Testing: Growth Regulators 6.1 Moderators of Growth 6.2 Personnel Acceptance 6.3 Key People for Women's Health Testing 6.4 Key Elements for Women's Health Testing 6.5 Women's Health Testing and Reimbursement 6.6 Rapid Near-Patient Testing in Hospitals 6.7 Satellite Facilities 6.8 Regionalization of Laboratory Care 6.9 Requirements for Women's Health Testing 6.10 Clinical Laboratory Improvement Act of 1988 (CLIA) 7. Business Trends in the Industry 8. Important Technology Trends 9. Company Profiles Companies Mentioned - Abbott Diagnostics - Becton Dickinson (BD) - Biomerica, Inc - Concateno Plc - Dilon Diagnostics - FujiFilm Medical Systems USA - General Electric Healthcare - Genzyme Corp - Hologic Inc - iCAD, Inc - Imaging Diagnostic Systems, Inc - Inverness Medical Innovations, Inc. (Alere) - Invivo Corp - Johnson & Johnson, Inc - Kyowa Medex Co., Ltd - Lantheus Medical Imaging, Inc - LifeScan Corporation - Mitsubishi Kagaku Iatron - Myraid Genetics, Inc - OraSure Technologies, Inc - Polymedco, Inc - Procrea Cliniques - QIAGEN in USA - Quest Diagnostics, Inc - Quidel Corp - Rad-Icon Imaging Corp - Roche Ltd - Siemens Medical Solutions USA, Inc - Vidar Systems Corp For more information visit http://www.researchandmarkets.com/research/nm...ens_health
Biomerica Announces Year End Results -- Sales Up Over 6%
Marketwire - Fri Aug 30, 7:19AM CDT
Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, today reported net sales for the fiscal year 2013 were $6,472,960 versus net sales of $6,081,131 in fiscal 2012, an increase of 6.4%. Net cash flow from operating activities was $1,394,037 for fiscal year ended May 31, 2013 compared with $147,412 for the 2012 year end. Income from operations was $514,008 for fiscal 2013 compared to $504,999 for fiscal 2012 reflecting an increase in Research and Development spending of over $111,000 for the current fiscal year compared to the previous year. Net Income was flat at $0.08 per share for the fiscal year ended May 31, 2013 compared to net income of $0.08 per share, in fiscal 2012.
Biomerica Receives Approval to Market Its H. Pylori and PTH Products in Mexico and Appoints New Distributor in Mexico
Marketwire - Wed Aug 07, 7:19AM CDT
Biomerica, Inc. (OTCBB: BMRA) announced today that it has received approval to market and sell its H. Pylori and Parathyroid Hormone (PTH) diagnostic tests in Mexico. The company also announced that it has appointed a new distributor in Mexico with over 35 years of experience and 200 employees overall.
Cancer Diagnostic Testing World Markets 2013
M2 - Tue Apr 30, 11:01AM CDT
Research and Markets has announced the addition of the "Cancer Diagnostic Testing World Markets" report to their offering. Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs of the disease are $126 billion annually. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this TriMark Publications report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are t
Diabetes Diagnostics - Global Strategic Business Report
M2 - Tue Feb 05, 5:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/dnsz3x/diabetes) has announced the addition of the "Diabetes Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Diabetes Diagnostics in US$ Million by the following Product Segments: - Blood Glucose Testing Devices (Blood Glucose Test Kit, Blood Glucose Meter/Monitor, Diabetes Kit, & Diabetes Tracking System) - Diabetes Testing Supplies (Blood Glucose Test Strips, Lancet, Lancet Device, Reagent Strip) - Others (Including Blood Glucose Sensors, Control Solution, and Reagent Tablets). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 62 companies including many key and niche players. Market data and analytics are derived from
Biomerica reports net income of USD26,544 for Q3
M2 - Wed Apr 16, 3:01AM CDT
Biomedical company Biomerica (OTCBB:BMRA) stated on Tuesday its net income of USD26,544 for the three months ended 28 February 2014.
Biomerica Announces Third Quarter Financial Results
Marketwire - Tue Apr 15, 7:19AM CDT
Biomerica, Inc. (OTCBB: BMRA) today reported net sales of $1,492,719 for the three months ending February 28, 2014, compared to $1,416,698 for the same period in the previous year. Sales for the nine months ending February 28, 2014 were $3,441,299, compared to $5,002,418.
Global Enteric Disease Testing Market 2014-2018: New Emerging Viruses and Bacteria Playing an Important Role in Diagnostics Industry
M2 - Wed Feb 26, 6:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/lrghlr/global_enteric) has announced the addition of the "Global Enteric Disease Testing Market 2014-2018" report to their offering. The analysts forecast the Global Enteric Disease Testing market to grow at a CAGR of 2.83 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing incidence of enteric diseases. The Global Enteric Disease Testing market has also been witnessing the emergence of new pathogens causing infections. However, the stringent regulatory approval could pose a challenge to the growth of this market. Key vendors dominating this space are Alere Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Cepheid Inc. and DiaSorin S.p.A. Other vendors mentioned in the report are Affymetrix Inc., Beckton, Dickenson and Co., Biomerica Inc., Coris BioConcept, Danaher Corp., Meridian Bioscience Inc., Quest Diagnostics Inc., R-Biopharm AG, and Trinity Biotech PLC. Commenting on the report, an analyst from the team said: Vendors are introducing new diagnostic tests for new found pathogens that are responsible for some other types of infectious diseases. These new pathogens include West Nile virus, respiratory syncytial virus, genital mycoplasma, C. difficile, norovirus, and rotavirus. C. difficile and rotavirus tests have seen the maximum level of acceptance in the market. Thus, the improvement in detection technology aiding in the identification of new pathogens is driving the need for enteric disease testing products. According to the report, one of the major drivers in the market is the increasing incidence of enteric diseases among the population, creating a need for testing methods that effectively diagnose diseases. For more information visit http://www.researchandmarkets.com/research/lr...al_enteric About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Concise Analysis on the International Enteric Disease Testing Market - Forecasts to 2019
M2 - Wed Feb 05, 5:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/v3x48h/enteric_disease) has announced the addition of the "Concise Analysis on the International Enteric Disease Testing Market - Forecasts to 2019" report to their offering. Various microbes responsible for enteric infections include salmonella, shigella, rotavirus, norovirus, c. difficile, cryptosporidium, vibrio and campylobacter. These diseases may range from asymptomatic to having mild to severe symptoms such as bloody diarrhea, abdominal cramps, stool containing blood or pus, fever and weight loss. Incubation period varies from few days to few weeks depending on the disease and severity. In order to reduce the chance of developing complications, these diseases needed to be diagnosed early. Earlier, diagnosis of enteric diseases relied on culture results of stool specimen that involved identification of causative pathogens in a culture medium. However, the trend is now shifting from culture methods to other diagnostic methods owing to limitations associated with culture tests. Major drawbacks associated with culture tests include high cost, labor intensive, requires sophisticated laboratory and a skilled person to perform the diagnosis. On the other hand, enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR) has made enteric infection diagnosis easy and fast. In developed regions such as North America and Europe, PCR based diagnosis is most recommended testing method for enteric diseases as it offers high sensitivity and specificity and is considered as easy, accurate, rapid and reliable method of diagnosis. Latest introductions in MALDI-TOF have also been developed for rapid diagnosis of whole organisms without destruction of infection sample. Asia-Pacific accounting for more than 50% of the total global population represents the most profitable market for enteric disease testing in terms of growth and potential. Key Topics Covered: 1 Preface 2 Executive Summary 3 Enteric Disease Testing Market Overview 4 Global Enteric Disease Testing Market 5 Global Enteric Disease Testing Market, By Geography, 2011 - 2019 6 Key Player Analysis for Enteric Disease Testing Market, 2012 7 Company Profiles Companies Mentioned: - Alere - Becton Dickinson & Company - Biomerica - Biomerieux - Bio-Rad - Cepheid - Coris Bioconcept - Diasorin - Meridian Bioscience - Quest Diagnostics - Trinity Biotech For more information visit http://www.researchandmarkets.com/research/v3...ic_disease
Merriman Capital Initiates on Biomerica, Inc. with a Buy Rating
Thomson Reuters ONE - Fri Jan 24, 9:29AM CST
SAN FRANCISCO - January 24, 2014 - Merriman Capital, Inc. ("Merriman"
, a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced that it has initiated equity research coverage of Biomerica, Inc. (OTCQB: BMRA) with a Buy rating and a $2.85 price target. Biomerica Announces Completion of Strategic Investment
Marketwire - Wed Jan 22, 7:19AM CST
Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, today reported it has closed a strategic investment from its new China distribution partner. In total the new China partner has now invested $500,000 at $1.25 per share for 400,000 shares of Biomerica restricted common stock.
Prefeasibility Report on a Peanut Butter Manufacturing Plant
M2 - Fri Jan 17, 4:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/5kjt3t/prefeasibility) has announced the addition of the "Prefeasibility Report on a Peanut Butter Manufacturing Plant" report to their offering. Prefeasibility Report on a Peanut Butter Manufacturing Plant provides a techno-commercial roadmap for setting up a peanut butter manufacturing plant. The study, which has been done by one of the world's leading research and advisory firms, covers all the requisite aspects of the peanut butter industry. This ranges from macro overview of the market to micro details of the industry performance, processing & manufacturing requirements, project cost, project funding, project economics, expected returns on investment, profit margins, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who are planning to foray into the peanut butter industry in any manner. Key Questions Answered in This Report? - What are the key success and risk factors in the peanut butter industry? - How has the peanut butter market performed so far and how will it perform in the coming years? - What is the structure of the peanut butter industry and who are the key players? - What are the various unit operations involved in a peanut butter plant? - What is the total size of land required for setting up a peanut butter plant? - What are the machinery requirements for setting up a peanut butter plant? - What are the raw material requirements for setting up a peanut butter plant? - What are the utility requirements for setting up a peanut butter plant? - What are the manpower requirements for setting up a peanut butter plant? - What are the infrastructure costs for setting up a peanut butter plant? - What are the capital costs for setting up a peanut butter plant? - What are the operating costs for setting up a peanut butter plant? - What should be the pricing mechanism of various peanut butter products? - What will be the income and expenditures for a peanut butter plant? - What is the time required to break-even? *Please note that this is a prefeasibility report. It will be delivered to you within 10-12 days after the confirmation of payment Key Topics Covered: 1. Executive Summary 2. Introduction to the Peanut Butter Industry 3. Peanut Butter Industry Analysis 4. Processing & Manufacturing of Peanut Butter Products 5. Project Details, Requirements and Costs Involved 6. Peanut Butter Manufacturing Plant: Loans & Financial Assistance 7. Peanut Butter Manufacturing Plant: Project Economics 8. Appendix For more information visit http://www.researchandmarkets.com/research/5k...easibility About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Biomerica Inc falls to net loss of USD243,357 in Q2
M2 - Thu Jan 16, 9:46AM CST
Biomedical company Biomerica Inc (OTCBB:BMRA) on Wednesday reported a net loss of USD243,357, or USD0.03 per share, for the three months ended 30 November 2013.
GKN's Marcus Bryson to become President of UK trade organisation ADS Group
M2 - Wed Jan 15, 9:49AM CST
Aerospace
Biomerica Announces Second Quarter Financial Results
Marketwire - Wed Jan 15, 7:28AM CST
Biomerica, Inc. (OTCBB: BMRA) today reported net sales of $934,841 for the three months ended November 30, 2013, compared to $1,883,771 for the same period in the previous year. Net sales were $1,948,580 for the first six months of fiscal 2014 compared to $3,585,719 for the first six months in fiscal 2013.
10-Q: BIOMERICA INC
Edgar Online - Tue Jan 14, 3:25PM CST
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Biomerica to Supply Two of Its Point of Care Products to Multinational Pharmaceutical Company With Over $40 Billion in Sales
Marketwire - Tue Jan 14, 7:19AM CST
Biomerica, Inc. (OTCBB: BMRA) announced today it will supply two of its point of care products to a multinational pharmaceutical company for distribution in one European country with the possibility of expanding into multiple other countries throughout Europe. In addition, the multinational company is considering distribution of other Biomerica point of care products. The multinational pharmaceutical company that will be distributing Biomerica's products has over $40 billion in revenues and over 70,000 employees worldwide. The terms of the agreement were not disclosed and will remain confidential.
Global Enteric Disease Testing Market Forecasts & Opportunities Report, 2019
M2 - Fri Dec 06, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/n6mlmk/enteric_disease) has announced the addition of the "Global Enteric Disease Testing Market Forecasts & Opportunities Report, 2019" report to their offering. The global marketis expected to reach USD 3,643.4 million by 2019, up from USD 3,082.6 million in 2012, growing at a CAGR of 2.4% throughout the forecast period. Enteric diseases are gastrointestinal infections caused by a variety of microbes such as bacteria, viruses and parasites when they enter the body through the mouth or intestinal systems. Various microbes responsible for enteric infections include salmonella, shigella, rotavirus, norovirus, c. difficile, cryptosporidium, vibrio and campylobacter. These diseases may range from asymptomatic to having mild to severe symptoms such as bloody diarrhea, abdominal cramps, stool containing blood or pus, fever and weight loss. Incubation period varies from few days to few weeks depending on the disease and severity. In order to reduce the chance of developing complications, these diseases needed to be diagnosed early. The market for the enteric disease testing market has been segmented on the basis of different types of enteric diseases and their testing. Earlier, diagnosis of enteric diseases relied on culture results of stool specimen that involved identification of causative pathogens in a culture medium. However, the trend is now shifting from culture methods to other diagnostic methods owing to limitations associated with culture tests. Major drawbacks associated with culture tests include high cost, labor intensive, requires sophisticated laboratory and a skilled person to perform the diagnosis. On the other hand, enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR) has made enteric infection diagnosis easy and fast. In developed regions such as North America and Europe, PCR based diagnosis is most recommended testing method for enteric diseases as it offers high sensitivity and specificity and is considered as easy, accurate, rapid and reliable method of diagnosis. Latest introductions in MALDI-TOF have also been developed for rapid diagnosis of whole organisms without destruction of infection sample. Scope of the Report Diseases Bacterial Enteric Disease Testing Market - C.difficile Infection - Campylobacteriosis - Cholera - E.coli Infection - H.pylori Infection - Salmonellosis - Shigellosis Viral Enteric Disease Testing Market - Rotavirus Infection - Norovirus Infection Parasitic Enteric Disease Testing Market - Amebiasis - Cryptosporidiosis - Giardiasis Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Enteric Disease Testing Market Overview Chapter 4 Global Enteric Disease Testing Market Chapter 5 Global Enteric Disease Testing Market, By Geography, 2011 - 2019 (USD Million) Chapter 6 Key Player Analysis for Enteric Disease Testing Market, 2012 Chapter 7 Company Profiles - Alere, Inc - Becton Dickinson & Company - Biomerica, Inc - Biomerieux - Bio-Rad - Cepheid - Coris Bioconcept - Diasorin - Meridian Bioscience, Inc - Quest Diagnostics - Trinity Biotech For more information visit http://www.researchandmarkets.com/research/n6...ic_disease
Global Women's Health Diagnostic Testing Market Report 2013
M2 - Fri Nov 15, 5:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/nmsm9b/womens_health) has announced the addition of the "Global Women's Health Diagnostic Testing Market Report 2013" report to their offering. The purpose of this report is to describe the specific segment of the in vitro diagnostics (IVDs) market called women's health testing. This study includes contemporary and generally accepted clinical and analytical activities. This analysis examines clinical measurement devices, as well as their reagents and supplies, as utilized in hospitals, clinics and doctor's offices. Some diagnostic tests, which are marketed primarily as over-the-counter products, are included in this report. This report also includes other important tests like mammography, (i.e., tests which are not generally associated with IVD tests, but which are an important component of the overall women's health market). Key Topics Covered: 1. Overview 2. Introduction - Sector Overview 3. Women's Health Testing Market Analysis in Size, Growth and Share 4. Women's Health Testing Individual Markets 5. World Mammography Market 6. Women's Health Testing: Growth Regulators 6.1 Moderators of Growth 6.2 Personnel Acceptance 6.3 Key People for Women's Health Testing 6.4 Key Elements for Women's Health Testing 6.5 Women's Health Testing and Reimbursement 6.6 Rapid Near-Patient Testing in Hospitals 6.7 Satellite Facilities 6.8 Regionalization of Laboratory Care 6.9 Requirements for Women's Health Testing 6.10 Clinical Laboratory Improvement Act of 1988 (CLIA) 7. Business Trends in the Industry 8. Important Technology Trends 9. Company Profiles Companies Mentioned - Abbott Diagnostics - Becton Dickinson (BD) - Biomerica, Inc - Concateno Plc - Dilon Diagnostics - FujiFilm Medical Systems USA - General Electric Healthcare - Genzyme Corp - Hologic Inc - iCAD, Inc - Imaging Diagnostic Systems, Inc - Inverness Medical Innovations, Inc. (Alere) - Invivo Corp - Johnson & Johnson, Inc - Kyowa Medex Co., Ltd - Lantheus Medical Imaging, Inc - LifeScan Corporation - Mitsubishi Kagaku Iatron - Myraid Genetics, Inc - OraSure Technologies, Inc - Polymedco, Inc - Procrea Cliniques - QIAGEN in USA - Quest Diagnostics, Inc - Quidel Corp - Rad-Icon Imaging Corp - Roche Ltd - Siemens Medical Solutions USA, Inc - Vidar Systems Corp For more information visit http://www.researchandmarkets.com/research/nm...ens_health
Biomerica Announces Year End Results -- Sales Up Over 6%
Marketwire - Fri Aug 30, 7:19AM CDT
Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, today reported net sales for the fiscal year 2013 were $6,472,960 versus net sales of $6,081,131 in fiscal 2012, an increase of 6.4%. Net cash flow from operating activities was $1,394,037 for fiscal year ended May 31, 2013 compared with $147,412 for the 2012 year end. Income from operations was $514,008 for fiscal 2013 compared to $504,999 for fiscal 2012 reflecting an increase in Research and Development spending of over $111,000 for the current fiscal year compared to the previous year. Net Income was flat at $0.08 per share for the fiscal year ended May 31, 2013 compared to net income of $0.08 per share, in fiscal 2012.
Biomerica Receives Approval to Market Its H. Pylori and PTH Products in Mexico and Appoints New Distributor in Mexico
Marketwire - Wed Aug 07, 7:19AM CDT
Biomerica, Inc. (OTCBB: BMRA) announced today that it has received approval to market and sell its H. Pylori and Parathyroid Hormone (PTH) diagnostic tests in Mexico. The company also announced that it has appointed a new distributor in Mexico with over 35 years of experience and 200 employees overall.
Cancer Diagnostic Testing World Markets 2013
M2 - Tue Apr 30, 11:01AM CDT
Research and Markets has announced the addition of the "Cancer Diagnostic Testing World Markets" report to their offering. Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs of the disease are $126 billion annually. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this TriMark Publications report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are t
Diabetes Diagnostics - Global Strategic Business Report
M2 - Tue Feb 05, 5:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/dnsz3x/diabetes) has announced the addition of the "Diabetes Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Diabetes Diagnostics in US$ Million by the following Product Segments: - Blood Glucose Testing Devices (Blood Glucose Test Kit, Blood Glucose Meter/Monitor, Diabetes Kit, & Diabetes Tracking System) - Diabetes Testing Supplies (Blood Glucose Test Strips, Lancet, Lancet Device, Reagent Strip) - Others (Including Blood Glucose Sensors, Control Solution, and Reagent Tablets). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 62 companies including many key and niche players. Market data and analytics are derived from
